Company intelligence / Profile preview

Forest Hills Lab

Hong Kong, Hong Kongforesthillslab.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Forest Hills Lab is advancing a multi-modal pipeline of seven potentially disease-modifying neurological assets. Lead programs target Parkinson's and Alzheimer's diseases. Clinical progress includes an IND-approved new chemical entity entering Phase 1, another candidate nearing Phase 2 for Parkinson's, and preclinical evidence showing reduction of alpha-synuclein and amyloid-beta in animal models.[4][5]

Therapeutic areas: Neurology
Modalities: Small molecules[5]
Industry: Biotech

Drug pipeline

1 asset

FHL-101

Unknown

Partnerships

Rush University – licensing multiple candidates from Dr. Kalipada Pahan's lab at Rush University Medical Center.[5]

Beyond the preview

Go deeper on Forest Hills Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forest Hills Lab.

Explore the full profile